Previous 10 | Next 10 |
ObsEva SA (OBSV) Q1 2019 Results Earnings Conference Call May 09, 2019 08:00 AM ET Company Participants Mario Corso - Senior Director, Investor Relations Ernest Loumaye - Co-Founder and Chief Executive Officer Jean-Pierre Gotteland - Chief Scientific Officer Wim Souverijns - Ch...
ObsEva (NASDAQ: OBSV ): Q1 GAAP EPS of -$0.59 misses by $0.09 . More news on: ObsEva SA, Earnings news and commentary, Healthcare stocks news, Read more ...
2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids; MAA submission for nolasiban IVF therapy targeted by year-end GENEVA, Switzerland and BOSTON, MA. (May 9, 2019...
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive hea...
Geneva, Switzerland and Boston, MA – May 8, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive hea...
Long-term data from a Phase 2b clinical trial, EDELWEISS , evaluating ObsEva SA's (NASDAQ: OBSV ) linzagolix for the treatment of endometriosis-associated pelvic pain showed a durable treatment benefit with the daily 75 mg and 200 mg doses. More news on: ObsEva SA, Healthcare stocks ne...
Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel thera...
Geneva, Switzerland and Boston, MA –May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive healt...
ObsEva SA (NASDAQ: OBSV ) announces additional neonatal and infant follow-up results from the IMPLANT2 Phase 3 trial of its oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF procedures. More news on: ObsEva SA, Healthcare stocks news, Read more ...
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive h...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...